0000899243-23-011942.txt : 20230501
0000899243-23-011942.hdr.sgml : 20230501
20230501164128
ACCESSION NUMBER: 0000899243-23-011942
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230427
FILED AS OF DATE: 20230501
DATE AS OF CHANGE: 20230501
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Henn Matthew R.
CENTRAL INDEX KEY: 0001767321
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37465
FILM NUMBER: 23874424
MAIL ADDRESS:
STREET 1: C/O SERES THERAPEUTICS, INC.
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seres Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274326290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617 945 9626
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Seres Health, Inc.
DATE OF NAME CHANGE: 20140603
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-27
0
0001609809
Seres Therapeutics, Inc.
MCRB
0001767321
Henn Matthew R.
C/O SERES THERAPEUTICS, INC.
200 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
See Remarks
0
Stock Option (Right to Buy)
10.84
2023-04-27
4
A
0
35000
0.00
A
2023-04-27
2027-06-18
Common Stock
35000
70000
D
On June 19, 2017, the Reporting Person was granted an option to purchase 70,000 shares of the Issuer's common stock. The option vested and became exercisable in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in vesting of the option as to 35,000 shares.
Chief Scientific Officer and EVP
/s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn
2023-05-01